AKESO (09926) announced that its indirect wholly-owned subsidiaries, Zhongshan Akeso Biopharma Co., Ltd. and Kangrong Oriental (Guangdong) Pharmaceutical Co., Ltd. (collectively referred to as "AKESO"), have recently entered into an Exclusive Commercialization Rights Agreement with Hubei Jumpcan Pharmaceutical Co.,Ltd.'s wholly-owned subsidiary, Jumpcan Pharmaceutical Group Co., Ltd., and Jiangsu Jiyuan Pharmaceutical Co., Ltd. (collectively referred to as "Jumpcan Pharmaceutical"). Under this agreement, AKESO has granted Jumpcan Pharmaceutical the exclusive rights to commercialize Yixining® (Inclisiran Injection), a drug independently developed and approved for marketing by the company, within the People's Republic of China (excluding Hong Kong, Macau, and Taiwan) for the duration of the collaboration. For this partnership, AKESO will receive an authorization fee of RMB 80 million (including tax) paid by Jumpcan Pharmaceutical, along with milestone payments of up to RMB 10 million (including tax). Jumpcan Pharmaceutical will be responsible for the commercial promotion and sales of Yixining® in the authorized market. Yixining® (Inclisiran Injection) is a novel PCSK9 monoclonal antibody drug independently developed by the company, which received market approval in September 2024 for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients with atherosclerotic cardiovascular disease. Currently, Yixining® has been included in the latest National Reimbursement Drug List (NRDL) and is strongly recommended by key Chinese expert consensus documents, including the 2025 Chinese Expert Consensus on Comprehensive Management of Cardiovascular Risk Associated with Blood Lipids and the 2025 Guidelines for Rational Drug Use and Comprehensive Management of Dyslipidemia in County-Level Healthcare. Yixining® works by specifically binding to PCSK9 and blocking its interaction with the LDL receptor (LDL-R), thereby restoring LDL-R expression levels and enhancing the clearance of LDL-C from the plasma. Previous studies have shown that treatment with PCSK9 monoclonal antibodies, on top of statin background therapy, can significantly reduce cholesterol levels in humans and lower the risk of heart attack and stroke in patients. Phase III clinical studies demonstrated that Yixining® has excellent clinical efficacy for patients stratified as very high-risk, high-risk, and moderate-to-low risk, as well as for patients regardless of their baseline LDL-C levels, offering a new option for the clinical treatment of hypercholesterolemia and the long-term control of cardiovascular risk.